SLC18A2 and Parkinson disease: The discrepancy has led to the hypothesis that PD patients may reach the pathological threshold earlier in life due to accelerated NMG formation, potentially driven by dysregulation of other enzymes such as L-dopachrome tautomerase or VMAT2 [46].